A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients
Condition: Gout Interventions: Drug: Epaminurad 6 mg; Drug: Epaminurad 9 mg; Drug: Febuxostat 40 mg; Drug: Febuxostat 80 mg; Drug: Epaminurad 6 mg placebo; Drug: Epaminurad 9 mg placebo; Drug: Febuxostat 40 mg placebo; Drug: Febuxostat 80 mg placebo Sponsor: JW Pharmaceutical Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2023 Category: Research Source Type: clinical trials
Phase 2b/3 Study to Assess Efficacy and Safety of ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
Condition: Gout Interventions: Drug: ABP-671; Drug: Allopurinol; Other: Placebo Sponsor: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2023 Category: Research Source Type: clinical trials
A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients
Condition: Gout Interventions: Drug: Epaminurad 6 mg; Drug: Epaminurad 9 mg; Drug: Febuxostat 40 mg; Drug: Febuxostat 80 mg; Drug: Epaminurad 6 mg placebo; Drug: Epaminurad 9 mg placebo; Drug: Febuxostat 40 mg placebo; Drug: Febuxostat 80 mg placebo Sponsor: JW Pharmaceutical Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2023 Category: Research Source Type: clinical trials
A Exploratory Trial of WTX221 in Refractory Gout Patients
Condition: Gout Tophus Intervention: Drug: WTX221 Sponsors: RenJi Hospital; Westlake Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels
Condition: Gout Interventions: Drug: PRX-115; Drug: Placebo Sponsor: Protalix Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 27, 2023 Category: Research Source Type: clinical trials
